A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A double-blind, randomized, placebo-controlled Phase I/II trial to evaluate the safety of
dapivirine Gel 4759, 0.05% 2.5 g and dapivirine Gel 4789, 0.05% 2.5 g formulations as
compared to the vaginal HEC-based Universal placebo gel, 2.5 g in healthy HIV-negative women